Figure 1. PRISMA 2020 flow diagram for new systematic reviews which included searches of databases and registers only.
Figure 2. Quality assessment using the Newcastle-Ottawa Scale for cohort studies [13,14,15,16,17,18,19,20]. Figure 3. Overall and individual study estimates of the weighted mean difference of Galectin-3 are shown in patients receiving cancer treatment. Parallelogram boxes for weighted mean difference and horizontal lines represent 90% confidence interval (CI). Subgroup analyses were carried out independently for country (A), the presence of doxorubicin (B) and measurement (C) [14,15,17,18,19]. Figure 4. Cancer-therapy-related cardiotoxicity as measured by a standardized left ventricular ejection fraction decrease with no considerable Galectin-3 change. Parallelogram boxes for hazard ratio, and horizontal lines represent 90% confidence interval (CI) [15,19]. Figure 5. (A) Overall and individual study estimates of the standardized mean difference of MPO are shown in patients receiving cancer treatment. Parallelogram boxes for standardized mean difference, and horizontal lines represent 90% confidence interval (CI). (B) Cancer-therapy-related cardiotoxicity as measured by a standardized left ventricular ejection fraction decrease with significant MPO change. Parallelogram boxes for hazard ratio, and horizontal lines represent 90% confidence interval (CI) [13,16,17,19,20].Figure 6. The potential mechanism of MPO increasing after cancer therapy. MPO: myeloperoxidase; NETs: neutrophil extracellular traps.
Table 1. Study Characteristics. Values are expressed as mean ± SD or median [interquartile range] for continuous variables. LVEF: Left Ventricular Ejection Fraction; gal-3: galectin-3; MPO: myeloperoxidase. +: The main outcome event occurred, but the number of events was not extracted; —: No accurate data were extracted. ①②: Age distribution of different interventions.
Table 1. Study Characteristics. Values are expressed as mean ± SD or median [interquartile range] for continuous variables. LVEF: Left Ventricular Ejection Fraction; gal-3: galectin-3; MPO: myeloperoxidase. +: The main outcome event occurred, but the number of events was not extracted; —: No accurate data were extracted. ①②: Age distribution of different interventions.
Study CharacteristicsAuthorYearSample
留言 (0)